176
Participants
Start Date
November 30, 2010
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2016
Imatinib mesylate
Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
Placebo
Placebo
Columbia University, New York
Temple University, Philadelphia
University of Alabama, Birmingham
Cleveland Clinic, Cleveland
University of Wisconsin, Madison
Washington University School of Medicine, St Louis
Brigham and Womens Hospital, Boston
Collaborators (1)
Baim Institute for Clinical Research
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Brigham and Women's Hospital
OTHER